Abeona Therapeutics Inc. (ABEO) Investor Relations Documents

Abeona Therapeutics Inc. (ABEO) investor relations documents from the company's IR site: 2 presentations, 36 press releases; latest deck 2026-06-12. Read in-app with summaries. First-party data.

Corporate Presentation: Abeona Therapeutics is a commercial-stage gene therapy company whose lead product, ZEVASKYN, is an FDA-approved, one-time treatment for RDEB.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-13Press releaseAbeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
2026-08-06Press releaseAbeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
2026-08-04Press releaseCMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
2026-08-03Press releaseAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-21Press releaseCincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
2026-07-01Press releaseAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-12PresentationCorporate Presentation
2026-06-01Press releaseAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-26Press releaseAbeona Therapeutics® Announces Participation in Upcoming Investor Conferences
2026-05-13Press releaseAbeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
2026-05-11Press releaseAbeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for
2026-05-04Press releaseAbeona Therapeutics® Announces Date of First Quarter Financial Results
2026-04-14PresentationDownload Corporate Presentation
2026-03-17Press releaseAbeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
2026-03-03Press releaseAbeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2
Press releaseAbeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates
Press releaseAbeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
Press releaseAbeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
2025-03-20Press releaseAbeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch P
2024-11-14Press releaseAbeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
2024-08-12Press releaseAbeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upc
2024-05-15Press releaseAbeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
2024-03-18Press releaseEarnings ReleaseHTML
2023-11-13Press releaseEarnings ReleaseHTML
2023-08-08Press releaseEarnings ReleaseHTML
2023-05-11Press releaseEarnings ReleaseHTML
2023-03-29Press releaseEarnings ReleaseHTML
2022-11-14Press releaseEarnings ReleaseHTML
2022-08-11Press releaseEarnings ReleaseHTML
2022-05-13Press releaseEarnings ReleaseHTML
2022-03-31Press releaseEarnings ReleaseHTML
2021-11-15Press releaseEarnings ReleaseHTML
2021-07-28Press releaseEarnings ReleaseHTML
2021-05-18Press releaseEarnings ReleaseHTML
2021-03-24Press releaseEarnings ReleaseHTML
2020-11-09Press releaseEarnings ReleaseHTML
2020-08-10Press releaseEarnings ReleaseHTML
2020-05-06Press releaseEarnings ReleaseHTML

ABEO overview · ABEO earnings · ABEO financials · ABEO KPIs · ABEO ownership · ABEO peers · ABEO filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.